Literature DB >> 24868026

Two dimensions in targeting HER2.

Mark M Moasser1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24868026      PMCID： PMC4517047          DOI： 10.1200/JCO.2014.55.7652

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  67 in total

1.  Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth.

Authors:  David B Agus; Robert W Akita; William D Fox; Gail D Lewis; Brian Higgins; Paul I Pisacane; Julie A Lofgren; Charles Tindell; Douglas P Evans; Krista Maiese; Howard I Scher; Mark X Sliwkowski
Journal:  Cancer Cell       Date:  2002-08       Impact factor: 31.743

2.  Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2.

Authors:  M Cuello; S A Ettenberg; A S Clark; M M Keane; R H Posner; M M Nau; P A Dennis; S Lipkowitz
Journal:  Cancer Res       Date:  2001-06-15       Impact factor: 12.701

Review 3.  Monoclonal antibody therapy of human cancer: taking the HER2 protooncogene to the clinic.

Authors:  H M Shepard; G D Lewis; J C Sarup; B M Fendly; D Maneval; J Mordenti; I Figari; C E Kotts; M A Palladino; A Ullrich
Journal:  J Clin Immunol       Date:  1991-05       Impact factor: 8.317

4.  Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.

Authors:  F Michael Yakes; Wichai Chinratanalab; Christoph A Ritter; Walter King; Steven Seelig; Carlos L Arteaga
Journal:  Cancer Res       Date:  2002-07-15       Impact factor: 12.701

5.  Enhancement of the p27Kip1-mediated antiproliferative effect of trastuzumab (Herceptin) on HER2-overexpressing tumor cells.

Authors:  Radu Marches; Jonathan W Uhr
Journal:  Int J Cancer       Date:  2004-11-10       Impact factor: 7.396

6.  Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2.

Authors:  Roberto Gennari; Sylvie Menard; Francesco Fagnoni; Luisa Ponchio; Mario Scelsi; Elda Tagliabue; Fabio Castiglioni; Laura Villani; Cesare Magalotti; Nadia Gibelli; Barbara Oliviero; Bettina Ballardini; Gianantonio Da Prada; Alberto Zambelli; Alberto Costa
Journal:  Clin Cancer Res       Date:  2004-09-01       Impact factor: 12.531

7.  A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells.

Authors:  Edgar R Wood; Anne T Truesdale; Octerloney B McDonald; Derek Yuan; Anne Hassell; Scott H Dickerson; Byron Ellis; Christopher Pennisi; Earnest Horne; Karen Lackey; Krystal J Alligood; David W Rusnak; Tona M Gilmer; Lisa Shewchuk
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

8.  Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex.

Authors:  Matthew C Franklin; Kendall D Carey; Felix F Vajdos; Daniel J Leahy; Abraham M de Vos; Mark X Sliwkowski
Journal:  Cancer Cell       Date:  2004-04       Impact factor: 31.743

9.  ErbB3 is involved in activation of phosphatidylinositol 3-kinase by epidermal growth factor.

Authors:  S P Soltoff; K L Carraway; S A Prigent; W G Gullick; L C Cantley
Journal:  Mol Cell Biol       Date:  1994-06       Impact factor: 4.272

10.  Identification of c-erbB-3 binding sites for phosphatidylinositol 3'-kinase and SHC using an EGF receptor/c-erbB-3 chimera.

Authors:  S A Prigent; W J Gullick
Journal:  EMBO J       Date:  1994-06-15       Impact factor: 11.598
View more
  16 in total

Review 1.  Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies.

Authors:  Florian Schütz; Frederik Marmé; Christoph Domschke; Christof Sohn; Alexandra von Au
Journal:  Breast Care (Basel)       Date:  2018-01-31       Impact factor: 2.860

2.  Immunological Mechanisms in Breast Cancer - from Bench to Bedside.

Authors:  Carsten Denkert; Florian Schütz
Journal:  Breast Care (Basel)       Date:  2016-04-27       Impact factor: 2.860

3.  Inactivating Amplified HER2: Challenges, Dilemmas, and Future Directions.

Authors:  Mark M Moasser
Journal:  Cancer Res       Date:  2022-08-16       Impact factor: 13.312

4.  Mass-spectrometry-based quantitation of Her2 in gastroesophageal tumor tissue: comparison to IHC and FISH.

Authors:  Daniel V T Catenacci; Wei-Li Liao; Lei Zhao; Emma Whitcomb; Les Henderson; Emily O'Day; Peng Xu; Sheeno Thyparambil; David Krizman; Kathleen Bengali; Jamar Uzzell; Marlene Darfler; Fabiola Cecchi; Adele Blackler; Yung-Jue Bang; John Hart; Shu-Yuan Xiao; Sang Mee Lee; Jon Burrows; Todd Hembrough
Journal:  Gastric Cancer       Date:  2015-11-18       Impact factor: 7.370

5.  Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.

Authors:  M G Kris; D R Camidge; G Giaccone; T Hida; B T Li; J O'Connell; I Taylor; H Zhang; M E Arcila; Z Goldberg; P A Jänne
Journal:  Ann Oncol       Date:  2015-04-21       Impact factor: 32.976

6.  CD47 blockade augmentation of trastuzumab antitumor efficacy dependent on antibody-dependent cellular phagocytosis.

Authors:  Li-Chung Tsao; Erika J Crosby; Timothy N Trotter; Pankaj Agarwal; Bin-Jin Hwang; Chaitanya Acharya; Casey W Shuptrine; Tao Wang; Junping Wei; Xiao Yang; Gangjun Lei; Cong-Xiao Liu; Christopher A Rabiola; Lewis A Chodosh; William J Muller; Herbert Kim Lyerly; Zachary C Hartman
Journal:  JCI Insight       Date:  2019-12-19

7.  Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer.

Authors:  Andrea Rocca; Lorenzo Cecconetto; Alessandro Passardi; Elisabetta Melegari; Daniele Andreis; Manuela Monti; Roberta Maltoni; Samanta Sarti; Elisabetta Pietri; Alessio Schirone; Francesco Fabbri; Caterina Donati; Oriana Nanni; Anna Fedeli; Marina Faedi; Dino Amadori
Journal:  Cancer Chemother Pharmacol       Date:  2017-03-24       Impact factor: 3.333

8.  zzm321990 HER2-Positive Breast Cancer Patients with Pre-Treatment Axillary Involvement or Postmenopausal Status Benefit from Neoadjuvant Rather than Adjuvant Chemotherapy Plus Trastuzumab Regimens.

Authors:  Enora Laas; Arnaud Bresset; Jean-Guillaume Féron; Claire Le Gal; Lauren Darrigues; Florence Coussy; Beatriz Grandal; Lucie Laot; Jean-Yves Pierga; Fabien Reyal; Anne-Sophie Hamy
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

Review 9.  Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.

Authors:  Li-Chung Tsao; Jeremy Force; Zachary C Hartman
Journal:  Cancer Res       Date:  2021-06-18       Impact factor: 13.312

10.  TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting.

Authors:  George Fountzilas; Eleni Giannoulatou; Zoi Alexopoulou; Flora Zagouri; Eleni Timotheadou; Kyriaki Papadopoulou; Sotiris Lakis; Mattheos Bobos; Christos Poulios; Maria Sotiropoulou; Aggeliki Lyberopoulou; Helen Gogas; George Pentheroudakis; Dimitrios Pectasides; Angelos Koutras; Christos Christodoulou; Christos Papandreou; Epaminontas Samantas; Pavlos Papakostas; Paris Kosmidis; Dimitrios Bafaloukos; Charisios Karanikiotis; Meletios-Athanassios Dimopoulos; Vassiliki Kotoula
Journal:  Oncotarget       Date:  2016-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.